UNASSIGNED: Objective   Midtrimester maternal serum @entity160 (MSAFP) and sonographic evaluation have been used to screen for @entity3570 . With the increased uptake of cell-free DNA (cfDNA) and first trimester screening, MSAFP levels may no longer be obtained routinely. Our aim was to evaluate a pediatric neurosurgical referral center database of @entity3570 cases to determine the antenatal detection rate and means of diagnosis. Study Design   Nested case series of all @entity3570 cases referred postnatally from 2007 to 2013. Data were abstracted from the maternal record and rates of antenatal detection with MSAFP and sonographic screening were determined. Results   Of the 105 postnatally referred cases, 11.4% (12/105) were not identified until delivery. Overall, 39% of the cases had MSAFP screening. The odds ratio for sonogram-based detection of @entity3570 was 4.9 (95% confidence interval, 2-11.9). Of the neonatally detected cases, 100% had prenatal care and 91.6% (11 of the 12 cases) had documented sonography. Conclusion   We have found that 11.4% of the @entity3570 cases were not detected before delivery. Nine out of the 12 cases of antenatally missed @entity3570 were not screened using MSAFP. Our findings support the approach of midtrimester MSAFP screening combined with sonographic evaluation. We speculate that prenatal screening with MSAFP is underutilized.

Role of Maternal Serum XXXX and Ultrasonography in Contemporary Detection of Spina Bifida.

@entity3570 :: ('MESH:D016135', 'Disease') :: ['spina bifida'] @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein']
@entity160 :: (174,Gene) :: ['Alpha-Fetoprotein']
